Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05810194
Other study ID # SPASX020
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 1, 2023
Est. completion date December 31, 2023

Study information

Verified date January 2024
Source Stratpharma AG
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Routinely collected data on radiation-induced skin toxicity from 2010 to 2022 will be retrospectively analyzed. Data will be split into two cohorts: patients that received 1) StrataXRT and 2) standard of care. The incidence of grade ≥ 2 radiation dermatitis, the time to onset of grade ≥ 2 radiation dermatitis, the radiation dose at onset of grade ≥ 2 radiation dermatitis, the incidence of moist desquamation and the number of treatment interruptions will be compared between the cohorts.


Recruitment information / eligibility

Status Completed
Enrollment 344
Est. completion date December 31, 2023
Est. primary completion date September 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosed with Head and Neck cancer treated with radiation therapy with or without chemotherapy - Fractionated courses including at least 30 fractions (treatments) - Minimum of 18 completed radiation treatments - Radiation dose: > 50 Gy - Radiation technique: IMRT - Radiation equipment: TrueBeam or Tomotherapy Exclusion Criteria: - Prior radiation to the treatment area - Patients with any medical condition such as active connective tissue disorder that predisposes them to an increased risk of potentially severe radiation dermatitis. - Patients undergoing SBRT - Patients with existing rashes or wounds in the target region or radiation therapy at RT start - Patients receiving hypofractionation - Patient receiving bolus

Study Design


Related Conditions & MeSH terms


Intervention

Device:
StrataXRT
StrataXRT® is a TGA-approved silicone-based topical preparation. StrataXRT is a self-drying, non-sticky, transparent, silicone gel formulation and when used as directed, dries to form an inert, thin, flexible wound dressing with a protective layer that is gas permeable and waterproof. It is the only self-drying topical silicone gel indicated for the use on radiation dermatitis, which hydrates and protects compromised skin areas and open wounds from chemical and microbial invasion. StrataXRT helps create an optimal wound healing environment which leads to faster re-epithelialization and a reduced inflammatory response. The product can be applied to fresh incisions and excisions, open wounds and compromised skin surfaces.
Drug:
Calendula
Calendula creams are over-the-counter (OTC) skin care ointments that are non-greasy, non-sticky, and quickly absorbed by the skin. Calendula is a topical agent derived from a plant of the marigold family Calendula Officinalis and is used in cuts, scrapes, chafing and minor burns. Containing numerous polyphenolic antioxidants, calendula has been studied in both the laboratory and clinical setting for the use in treating and preventing radiation induced skin toxicity.
Aquaphor
Aquaphor, containing 41 percent petrolatum (or petroleum jelly), temporarily protects minor cuts, scrapes, and burns; Aquaphor protects and helps relieve chapped or cracked skin and lips, as well as helps protecting from the drying effects of wind and cold weather.

Locations

Country Name City State
United States University of California Los Angeles California

Sponsors (1)

Lead Sponsor Collaborator
Stratpharma AG

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary CTCAE for Radiation Dermatitis Acute radiation dermatitis measured weekly during radiotherapy treatment, using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 score (grade 0 - 5). A higher grade is considered a worse outcome. 5 weeks
Secondary CTCAE for Hyperpigmentation Acute hyperpigmentation measured weekly during radiotherapy treatment, using the Common Terminology Criteria for Adverse Events (CTCAE) score (grade 0 - 2). A higher grade is considered a worse outcome. 5 weeks
Secondary Number of patients requiring burn cream application Total number of patients that required burn cream application during radiotherapy 5 weeks
Secondary Interval between radiotherapy start and burn cream application Number of days between initiation of radiation therapy and first application of burn cream during radiotherapy 5 weeks
Secondary Number of patients requiring Mepilex application Total number of patients that required Mepilex application during radiotherapy 5 weeks
Secondary Interval between radiotherapy start and Mepilex application Number of days between initiation of radiation therapy and first application of Mepilex during radiotherapy 5 weeks
See also
  Status Clinical Trial Phase
Completed NCT04059809 - Photobiomodulation for Breast Cancer Radiodermatitis Phase 2/Phase 3
Not yet recruiting NCT06040983 - Clinical Investigation on the Treatment of Radiation Induced Dermatitis With FR-101 Chest Dressing N/A
Withdrawn NCT05505214 - Topical Steroids & Bacterial Decolonization for Radiation Dermatitis Phase 2
Withdrawn NCT04593914 - A Novel Skin Barrier Protectant for Acute Radiodermatitis N/A
Completed NCT05450848 - StrataXRT vs. Standard Clinical Practice in the Prevention and Treatment of Radiation Dermatitis N/A
Active, not recruiting NCT05594498 - A Study of StrataXRT in the Prevention of Radiation Dermatitis in Breast Cancer Patients N/A
Recruiting NCT04110977 - A Reminder App to Reduce Radiation Dermatitis Rates in Patients With Head-and-Neck Cancer N/A
Recruiting NCT06158347 - Efficacy and Safety of Hyperbaric Oxygen Therapy for Radiation Dermatitis in Patients With Localized Breast Cancer N/A
Recruiting NCT05553392 - StrataXRT Versus Aquaphor for the Prevention and Management of Radiation Dermatitis N/A
Active, not recruiting NCT04268056 - Characterization of Skin Microbiome Profile and it's Correlation to Radiation Dermatitis
Not yet recruiting NCT04888234 - Evaluation the Effectiveness of Ru-Yi-Jin-Huang Powder for the Radiation-induced Dermatitis. Phase 2
Terminated NCT01597921 - A DB Randomized Study of R1 and R2 WaterJel / AloeVera Jell in Prevention of Radiation Dermatitis in Breast Cancer N/A
Completed NCT00481884 - Comparing RadiaPlexRx Hydrogel and Standard-of-Care for Radiation Dermatitis in Breast Cancer Patients Phase 3
Completed NCT03494205 - Urtica Comp. Gel for Prevention and Therapy of Radiation Dermatitis Phase 2
Completed NCT03941665 - Use of Gelronate Gel vs. Aloevera in Preventing/Minimizing Radiation-induced Dermatitis in Breast Cancer Patients N/A
Not yet recruiting NCT02051907 - Clinical Study to Evaluate Safety and Efficacy of KAM1403 Gel to Treat Radiation Dermatitis Phase 2
Completed NCT02839473 - Hydrosorb® Versus Control in the Management of Radio-induced Skin Toxicity: Multicentre Controlled Phase III Randomized Trial Phase 3
Completed NCT00876642 - Trial Comparing Best Supportive Care to Aloe Vera Gel Phase 3
Completed NCT00573365 - LED Photomodulation for Prevention of Post-Radiation Treatment Dermatitis N/A
Completed NCT03910595 - Efficacy Study of Mepitel Film the Prophylaxis of Radiation-Induced Skin Reactions in Breast Cancer Patients N/A